Sage Journals: Discover world-class research

Abstract

Background

Prior studies examined variants within presenilin-2 (PSEN2), presenilin-1 (PSEN1), and amyloid precursor protein (APP) genes. However, previously-reported clinically-relevant variants and other predicted damaging missense (DM) variants have not been characterized in a newer release of the Alzheimer's Disease Sequencing Project (ADSP).

Objective

To characterize previously-reported clinically-relevant variants and DM variants in PSEN2, PSEN1, APP within the participants from the ADSP.

Methods

We identified rare variants (MAF < 1%) in PSEN2, PSEN1, and APP in 14,641 individuals with whole genome sequencing and 16,849 individuals with whole exome sequencing available (N_total= 31,490). We additionally curated variants from ClinVar, OMIM, and Alzforum and report carriers of variants in clinical databases as well as predicted DM variants in these genes.

Results

We detected 31 previously-reported clinically-relevant variants with alternate alleles observed within the ADSP: 4 variants in PSEN2, 25 in PSEN1, and 2 in APP. The overall variant carrier rate for the 31 clinically-relevant variants in the ADSP was 0.3%. We observed that 79.5% of the variant carriers were cases compared to 3.9% were controls. In those with AD, the mean age of onset of AD among carriers of these clinically-relevant variants was 19.6 ± 1.4 years earlier compared with noncarriers (p = 7.8 × 10⁻⁵⁷). Additionally, we identified 197 rare variants (MAF < 1%) within ADSP participants not reported in known clinical databases.

Conclusions

A small proportion of individuals in the ADSP are carriers of a previously-reported clinically-relevant variant allele for AD and these participants have significantly earlier age of AD onset compared to noncarriers.

Keywords

Alzheimer's disease genetic databases genetic profile whole exome sequencing whole genome sequencing

Get full access to this article

View all access options for this article.

References

Chouraki

Seshadri

. Genetics of Alzheimer’s disease. Adv Genet 2014; 87: 245–294.

Cruchaga

Haller

Chakraverty

, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer’s disease families. PLoS One 2012; 7: e31039.

Lanoiselee

H-M

Nicolas

Wallon

, et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLoS Med 2017; 14: e1002270.

Beecham

Bis

Martin

, et al. The Alzheimer’s Disease Sequencing Project: study design and sample selection. Neurol Genet 2017; 3: e194.

Naj

Lin

Vardarajan

, et al. Quality control and integration of genotypes from two calling pipelines for whole genome sequence data in the Alzheimer’s disease sequencing project. Genomics 2019; 111: 808–818.

Leung

Valladares

Chou

Y-F

, et al. VCPA: genomic variant calling pipeline and data management tool for Alzheimer’s Disease Sequencing Project. Bioinformatics 2019; 35: 1768–1770.

Blue

Bis

Dorschner

, et al. Genetic variation in genes underlying diverse dementias may explain a small proportion of cases in the Alzheimer’s Disease Sequencing Project. Dement Geriatr Cogn Disord 2018; 45: 1–17.

Fernandez

Kim

Budde

, et al. Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer disease. PLoS Genet 2017; 13: e1007045.

PLINK 2 KING Cutoff, https://www.cog-genomics.org/plink/2.0/distance#make_king . 2023.

10.

Landrum

Lee

Benson

, et al. Clinvar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res 2018; 46: D1062–D1067.

11.

Amberger

Hamosh

. Searching Online Mendelian Inheritance in Man (OMIM): a knowledgebase of human genes and genetic phenotypes. Curr Protoc Bioinformatics 2017; 58: 1.2.1–1.2.12.

12.

Alzforum Mutations. https://www.alzforum.org/mutations .

13.

Chang

Chow

Tellier

, et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015; 4: 7–8.

14.

McLaren

Gil

Hunt

, et al. The Ensembl variant effect predictor. Genome Biol 2016; 17: 122–124.

15.

Liu

Mou

, et al. dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. Genome Med 2020; 12: 103–109.

16.

Liu

Jian

Boerwinkle

. dbNSFP: a lightweight database of human nonsynonymous SNPs and their functional predictions. Hum Mutat 2011; 32: 894–899.

17.

Wang

. Intervar: clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. Am J Hum Genet 2017; 100: 267–280.

18.

Arboleda-Velasquez

Lopera

O’Hare

, et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med 2019; 25: 1680–1683.

19.

Xiao

Liu

, et al. APP, PSEN1, and PSEN2 variants in Alzheimer’s disease: systematic re-evaluation according to ACMG guidelines. Front Aging Neurosci 2021; 13: 695808.

20.

Popejoy

Ritter

Crooks

, et al. The clinical imperative for inclusivity: race, ethnicity, and ancestry (REA) in genomics. Hum Mutat 2018; 39: 1713–1720.

21.

Manrai

Funke

Rehm

, et al. Genetic misdiagnoses and the potential for health disparities. N Engl J Med 2016; 375: 655–665.

22.

Spratt

Chan

Waldron

, et al. Racial/ethnic disparities in genomic sequencing. JAMA Oncol 2016; 2: 1070–1074.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.16 MB

Frequency of variants in Mendelian Alzheimer's disease genes within the Alzheimer's Disease Sequencing Project